BeyondSpring Inc. (NASDAQ:BYSI – Get Free Report) shares crossed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $0.66 and traded as high as $0.8970. BeyondSpring shares last traded at $0.8059, with a volume of 1,467,567 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings raised BeyondSpring from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, October 8th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock currently has an average rating of “Sell”.
View Our Latest Analysis on BYSI
BeyondSpring Trading Up 25.2%
BeyondSpring (NASDAQ:BYSI – Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.52.
About BeyondSpring
BeyondSpring Inc (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company’s lead product candidate is plinabulin, a small-molecule agent designed to provide both anticancer and immune-modulating effects.
Plinabulin has been investigated as a treatment to prevent chemotherapy-induced neutropenia, a potentially serious reduction in infection-fighting white blood cells that can occur during cancer treatment.
Read More
- Five stocks we like better than BeyondSpring
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AIāThese 5 Stocks Are Getting Paid
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.
